BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 16082890)

  • 1. [Beta-lactamases in laboratory and their role in resistance Part I.: Evolution of bacterial resistance mediated by beta-lactamases].
    Bedenić B
    Lijec Vjesn; 2004; 126(11-12):314-24. PubMed ID: 16082890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
    Susić E
    Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Beta-lactamases and their role in resistance. PART 2: beta-lactamases in 21st century].
    Bedenić B
    Lijec Vjesn; 2005; 127(1-2):12-21. PubMed ID: 16145868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinically important beta-lactamases of gram-negative bacteria: extended-spectrum beta-lactamases (ESBL)].
    Hrabák J
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):103-11. PubMed ID: 17900058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-spectrum beta-lactamases: an actual problem of hospital microbiology (a review).
    Szabó D; Barcs I; Rozgonyi F
    Acta Microbiol Immunol Hung; 1997; 44(4):309-25. PubMed ID: 9554165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolution of beta-lactamases.
    Bush K
    Ciba Found Symp; 1997; 207():152-63; discussion 163-6. PubMed ID: 9189640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What's new in antibiotic resistance? Focus on beta-lactamases.
    Babic M; Hujer AM; Bonomo RA
    Drug Resist Updat; 2006 Jun; 9(3):142-56. PubMed ID: 16899402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases.
    Shah AA; Hasan F; Ahmed S; Hameed A
    Res Microbiol; 2004; 155(6):409-21. PubMed ID: 15249058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bactericidal activity of oral beta-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-spectrum beta-lactamases.
    Bedenic B; Vranes J; Suto S; Zagar Z
    Int J Antimicrob Agents; 2005 Jun; 25(6):479-87. PubMed ID: 15894465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minor extended-spectrum beta-lactamases.
    Naas T; Poirel L; Nordmann P
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():42-52. PubMed ID: 18154527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
    Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases.
    Pfaller MA; Segreti J
    Clin Infect Dis; 2006 Apr; 42 Suppl 4():S153-63. PubMed ID: 16544266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Appearance of extended-spectrum beta-lactamases].
    Iyobe S
    Nihon Rinsho; 1997 May; 55(5):1219-24. PubMed ID: 9155178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Extended spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae].
    Bedenić B
    Lijec Vjesn; 1996 Oct; 118(10):244-8. PubMed ID: 9132524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New beta-lactamases: a paradigm for the rapid response of bacterial evolution in the clinical setting.
    Rossolini GM; Docquier JD
    Future Microbiol; 2006 Oct; 1(3):295-308. PubMed ID: 17661642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of newer beta-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002.
    Moland ES; Hanson ND; Black JA; Hossain A; Song W; Thomson KS
    J Clin Microbiol; 2006 Sep; 44(9):3318-24. PubMed ID: 16954267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of broad spectrum beta-lactamases on in vitro sensitivity of clinical isolates of Klebsiella pneumoniae to oral cephalosporins].
    Bedenić B; Singer S
    Lijec Vjesn; 2000; 122(1-2):8-13. PubMed ID: 10916350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens.
    Pfeifer Y; Cullik A; Witte W
    Int J Med Microbiol; 2010 Aug; 300(6):371-9. PubMed ID: 20537585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescein-labeled beta-lactamase mutant for high-throughput screening of bacterial beta-lactamases against beta-lactam antibiotics.
    Chan PH; Chan KC; Liu HB; Chung WH; Leung YC; Wong KY
    Anal Chem; 2005 Aug; 77(16):5268-76. PubMed ID: 16097768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.